DR. DAINIS IRBE M.D.
Prescription History 1013979665
Specialist in Eugene, OR


Quality Rating: 82.11 out of 100 score

NPI Status: Active since April 06, 2006

Contact Information

4725 VILLAGE PLAZA LOOP
SUITE 101
EUGENE, OR
ZIP 97401
Phone: (541) 683-3325

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DAINIS IRBE M.D., an active Specialist specialist practicing in Eugene, OR. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 107 documented patient claims. Among these therapy options, the most frequently utilized medication is Modafinil, which accounts for 26 claims alone.

Medication Index

No matching medications currently found on file.

Armodafinil

Generic Formulation: ArmodafinilSpecialty: Neurology
Provider Metrics Summary
Total Claims 20
30-Day Fills 36.0
Days Supply 1,080
OR State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills21.6
Peer Average Days Supply634
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,955.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$97.80

State Avg Cost Per Claim

$92.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.

Therapeutic Applications

Armodafinil reduces extreme sleepiness due to narcolepsy and other sleep disorders, such as periods of stopped breathing during sleep (obstructive sleep apnea). It is also used to help you stay awake during work hours if you have a work schedule that keeps you from having a normal sleep routine (shift work sleep disorder). This medication does not cure these sleep disorders and may not get rid of all your sleepiness. Armodafinil does not take the place of getting enough sleep. It should not be used to treat tiredness or hold off sleep in people who do not have a sleep disorder. It is not known how armodafinil works to keep you awake. It is thought to work by affecting certain substances in the brain that control the sleep/wake cycle.

Dextroamphetamine-Amphetamine

Generic Formulation: Dextroamphetamine/AmphetamineSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 488
OR State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.2
Peer Average Days Supply758
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $584.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.44

State Avg Cost Per Claim

$42.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills. This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.

Modafinil

Generic Formulation: ModafinilSpecialty: Neurology
Provider Metrics Summary
Total Claims 26
30-Day Fills 27.3
Days Supply 804
OR State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills27.3
Peer Average Days Supply804
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,611.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.99

State Avg Cost Per Claim

$151.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.

Therapeutic Applications

Modafinil reduces extreme sleepiness due to narcolepsy and other sleep disorders, such as periods of stopped breathing during sleep (obstructive sleep apnea). It is also used to help you stay awake during work hours if you have a work schedule that keeps you from having a normal sleep routine (shift work sleep disorder). This medication does not cure these sleep disorders and may not get rid of all your sleepiness. Modafinil does not take the place of getting enough sleep. It should not be used to treat tiredness or hold off sleep in people who do not have a sleep disorder. It is not known how modafinil works to keep you awake. It is thought to work by affecting certain substances in the brain that control the sleep/wake cycle.

Temazepam

Generic Formulation: TemazepamSpecialty: Neurology
Provider Metrics Summary
Total Claims 18
30-Day Fills 22.0
Days Supply 660
OR State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills23.2
Peer Average Days Supply678
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $394.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.94

State Avg Cost Per Claim

$16.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.

Therapeutic Applications

This medication is used to treat a certain sleep problem (insomnia). It may help you fall asleep faster, stay asleep longer, and lessen how often you wake up during the night, so you can get a better night's rest. Temazepam belongs to a class of drugs called benzodiazepines. It acts on your brain to produce a calming effect. Use of this medication is usually limited to short treatment periods of 1 to 2 weeks or less. If your insomnia continues for a longer time, talk to your doctor to see if you need other treatment.

Xyrem

Generic Formulation: Sodium OxybateSpecialty: Neurology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
OR State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.2
Peer Average Days Supply365
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $239,303.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,941.92

State Avg Cost Per Claim

$17,733.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The sodium salt of 4-hydroxybutyric acid. It is used for both induction and maintenance of ANESTHESIA.

Therapeutic Applications

This medication is used to treat narcolepsy, a condition that causes severe daytime sleepiness. Sodium oxybate can decrease daytime sleepiness and also reduce the number of sudden short attacks of weak/paralyzed muscles (known as cataplexy) that can occur in patients with narcolepsy. Sodium oxybate is a central nervous system depressant. It is also known as gamma hydroxybutyrate (GHB).

Xywav

Generic Formulation: Sodium,calcium,mag,pot OxybateSpecialty: Neurology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 348
OR State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.5
Peer Average Days Supply347
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $177,313.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,639.52

State Avg Cost Per Claim

$15,562.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat narcolepsy, a condition that causes severe daytime sleepiness. It can decrease daytime sleepiness and also reduce the number of sudden short attacks of weak/paralyzed muscles (known as cataplexy) that can occur in patients with narcolepsy. It may also be used to treat a certain sleep disorder (idiopathic hypersomnia). This medication is a central nervous system depressant. It is a form of a drug known as gamma hydroxybutyrate (GHB).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DAINIS IRBE M.D. provides transparency into local medical care patterns within Eugene, OR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.